Drug Trial Radar · NCT03881371
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Aug 1, 2019
Primary completion
Aug 20, 2021
Study completion Aug 20, 2021
Sponsor
- Lead sponsor
- Zambon SpAIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing motor fluctuations while on stable doses of Levodopa (L-dopa) (alone or in combination with other anti-Parkinson drugs). Eligible patients are required to meet the United Kingdom PD Society Brain Bank Clinical Diagnostic Criteria. The study involves a placebo group. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication. A total of 306 patients will be randomised into this study (153 in the safinamide and 153 in the placebo groups).
Conditions
- Parkinson Disease
Interventions
SafinamideDrug
At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
PlaceboOther
At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 16 in the Mean Total Daily "OFF" TimeTime frame: At baseline and Week 16
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Daqing Oilfield General Hospital 大庆油田总医院
Daqing, China
Fujian Medical University Union Hospital 福建医科大学附属协和医院
Fuzhou, China
Qilu Hospital of Shandong University 山东大学齐鲁医院
Jinan, China
Nanjing Drum Tower Hospital 南京鼓楼医院
Nanjing, China
The second affiliated hospital of Soochow University 苏州大学附属第二医院
Suzhou, China
Sir Run Run Shaw Hospital, Zhejiang University 浙江大学医学院附属邵逸夫医院
Hangzhou, No 3, Qing Chun East Road, China
Shanghai Ninth People's Hospital 上海交通大学医学院附属第九人民医院
Shanghai, No 639, Zhizaoju Road, China
Tianjin Union Medicine Center 天津市人民医院
Tianjin, No. 130, Jie Yuan Rd., Hong Qiao District, China
The Third Xiangya Hospital of Central South University 中南大学湘雅三医院
Changsha, No. 138, Tong Zi Po Road, He XI Yue Lu District, China
Renmin Hospital of Wuhan University 武汉大学人民医院
Wuhan, No. 238, Jie Fang Road, China
Sichuan Provincial People's Hospital 四川省医学科学院·四川省人民医院
Chengdu, No. 32 XI Er Duan, First Ring Road, Qing Yang District, China
West China Hospital, Sichuan University 四川大学华西医院
Chengdu, No. 37, Guoxue Alley, China
Beijing Friendship Hospital 首都医科大学附属北京友谊医院
Beijing, No. 6, Tiantan XI Li, Chongwen District, China
Beijing Tiantan Hospital Affiliated to Capital Medical University 首都医科大学附属北京天坛医院
Beijing, No. 6, Tiantan XI Li, Chongwen District, China
The First Bethune Hospital of Jilin University
Changchun, No. 71, Xin Min Street, China
The First Hospital of Shanxi Medical University 山西医科大学第一医院
Taiyuan, No. 85, Jie Fang South Road, China
The Second Affiliated Hospital of Zhejiang University 浙江大学医学院附属第二医院
Hangzhou, No. 88, Jie Fang Rd., China
The Second Affiliated Hospital of Nanchang University 南昌大学第二附属医院
Nanchang, No.1 Minde Road of Nanchang, China
Guangzhou First People's Hospital 广州市第一人民医院
Guangzhou, No.1 Panfu Rd., China
Shanghai General Hospital 上海市第一人民医院
Shanghai, No.100 Haining Road, China
Sun Yat-sen Memorial Hospital 中山大学孙逸仙纪念医院
Guangzhou, No.107, Yanjiang West Road, China
Tongji Hospital of Tongji University 同济大学附属同济医院
Wuhan, No.1095 Jiefang Avenue, China
The Third Hospital of Hebei Medical University 河北医科大学第三医院
Shijiazhuang, No.139.Zi Qiang Rd, China
Chongqing Three Gorges Central Hospital 重庆三峡中心医院
Chongqing, No.165 Xincheng Rd, Wanzhou District, China
Shanghai Ruijin Hospital 上海交通大学医学院附属瑞金医院
Shanghai, No.197 Ruijin Er Road, China
The First Affiliated Hospital of Baotou Medical University 内蒙古科技大学包头医学院第一附属医院
Baotou, No.41 Linyin Road, China
Baotou City Central Hospital 包头市中心医院
Baotou, No.61, Huancheng Road, Donghe District, China
The Affiliated Hospital of Xuzhou Medical University 徐州医科大学附属医院
Xuzhou, No.99, Huaihai West Road, Xuzhou, Jiangsu, China
The Affiliated Hospital Of Guiyang Medical College 贵州医科大学附属医院
Guiyang, No28. Guiyi Street, China
The First Affiliated Hospital of Guangzhou Medical University 广州医科大学附属第一医院
Guangzhou, Number 151, Yanjiang Road, China
Wenzhou Medical College-The First Affiliated Hospital 温州医科大学附属第一医院
Wenzhou, Shangcai Burg, Ouhai District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.